David John Garry, DO | |
6 Technology Dr, East Setauket, East Setauket, NY 11733-4079 | |
(631) 444-4686 | |
(631) 444-4622 |
Full Name | David John Garry |
---|---|
Gender | Male |
Speciality | Obstetrics/gynecology |
Experience | 35 Years |
Location | 6 Technology Dr, East Setauket, New York |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124117650 | NPI | - | NPPES |
01706376 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 184327 (New York) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Associates In Obstetrics And Gynecology University Faculty | 9032001045 | 93 |
News Archive
Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.
Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.
A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes
TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.
› Verified 6 days ago
Entity Name | Montefiore Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.
Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.
A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes
TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.
› Verified 6 days ago
Entity Name | University Associates In Obstetrics & Gynecology University Faculty P |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1538114723 PECOS PAC ID: 9032001045 Enrollment ID: O20040325001243 |
News Archive
Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.
Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.
A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes
TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
David John Garry, DO Po Box 1554, Stony Brook, NY 11790-0988 Ph: (631) 444-0650 | David John Garry, DO 6 Technology Dr, East Setauket, East Setauket, NY 11733-4079 Ph: (631) 444-4686 |
News Archive
Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.
Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.
A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes
TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.
› Verified 6 days ago
James Bernasko, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4 Technology Dr, Stony Brook University Physicians, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Todd R Griffin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Melissa Strafford, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Cecilia Avila, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Philip Schoenfeld, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 S Jersey Ave Unit 16, East Setauket, NY 11733 Phone: 631-689-6400 | |
Dr. Jennifer Marie Blaber, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 140 N Belle Mead Ave, East Setauket, NY 11733 Phone: 631-444-4686 |